Vericel Corporation (VCEL) Analysts See $-0.10 EPS

October 13, 2018 - By Marguerite Chambers

Vericel Corporation (NASDAQ:VCEL) Logo

Analysts expect Vericel Corporation (NASDAQ:VCEL) to report $-0.10 EPS on November, 6.They anticipate $0.06 EPS change or 37.50 % from last quarter’s $-0.16 EPS. After having $-0.12 EPS previously, Vericel Corporation’s analysts see -16.67 % EPS growth. The stock increased 4.17% or $0.53 during the last trading session, reaching $13.23. About 621,469 shares traded. Vericel Corporation (NASDAQ:VCEL) has risen 187.21% since October 14, 2017 and is uptrending. It has outperformed by 171.59% the S&P500.

Vericel Corporation (NASDAQ:VCEL) Ratings Coverage

Among 2 analysts covering Vericel Corp (NASDAQ:VCEL), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vericel Corp had 2 analyst reports since June 20, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Monday, July 16 by Ladenburg Thalmann. The stock of Vericel Corporation (NASDAQ:VCEL) has “Buy” rating given on Wednesday, June 20 by Leerink Swann.

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, makes, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company has market cap of $565.27 million. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. It currently has negative earnings. The firm also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.

Another recent and important Vericel Corporation (NASDAQ:VCEL) news was published by which published an article titled: “Vericel to Present at Multiple Upcoming Conferences” on September 21, 2018.

Vericel Corporation (NASDAQ:VCEL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News